FDA Depositions Reveal Crawford’s Prominent Role In Plan B Switch Review
This article was originally published in The Tan Sheet
Executive Summary
The role of high-level FDA officials in the review of Barr Labs' Rx-to-OTC switch application for Plan B was required by the "high-profile" nature of the NDA, according to Center for Drug Evaluation & Research Director Steven Galson
You may also be interested in...
A Brief But Memorable Tenure: Former US FDA Commissioner Lester Crawford Dies At 83
Crawford’s time as permanent FDA commissioner lasted less than three months and ended in scandal, but with that stint and his longer stretches as acting commissioner, he oversaw the agency through several historic moments that continue to influence the current regulatory environment.
Crawford Pleads Guilty Of Failing To Disclose Stocks In Firms FDA Regulates
Former FDA Commissioner Lester Crawford on Oct. 17 pleaded guilty in federal court to charges related to owning stocks in companies regulated by the agency
Crawford Pleads Guilty Of Failing To Disclose Stocks In Firms FDA Regulates
Former FDA Commissioner Lester Crawford on Oct. 17 pleaded guilty in federal court to charges related to owning stocks in companies regulated by the agency